Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Phytocannabinoids, particularly those derived from the Cannabis sativa plant such as cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), have been investigated for their potential in managing migraine. Historically, cannabis preparations were used in the 19th and early 20th centuries for headache relief, but modern scientific inquiry has provided a more structured evaluation of their efficacy. Several observational studies and small clinical trials suggest that phytocannabinoids may reduce the frequency and severity of migraine attacks in some individuals, possibly through modulation of the endocannabinoid system, which is involved in pain processing, inflammation, and neurotransmitter regulation.

However, the quality and quantity of evidence remain limited. Reviews, such as those published in Frontiers in Pharmacology (2018) and Current Pain and Headache Reports (2020), note promising findings but emphasize the lack of large, high-quality randomized controlled trials (RCTs). Dosing, cannabinoid composition, and long-term safety are not well established for migraine treatment. The American Headache Society does not currently recommend cannabinoids as a first-line therapy due to insufficient evidence.

In summary, while there is a scientific rationale and some supportive clinical data for the use of phytocannabinoids in migraine, the overall strength of the evidence is moderate at best (rated 3/5), and further research is necessary to establish efficacy, safety, and guidelines for clinical use.

More about Phytocannabinoid (unspecified)
More about Migraine

Other ingredients used for Migraine

Other health conditions supported by Phytocannabinoid (unspecified)

Products containing Phytocannabinoid (unspecified)